 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || GC203 TIL / Gencells Therapeutics
New P1 trial, Metastases: TIL-JC-DG-001: A Study on TIL for the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Jul 4, 2024
P1, N=30, Recruiting, Sponsor: Shanghai Juncell Therapeutics
- || GC203 TIL / Gencells Therapeutics
Enrollment open, Metastases: KUNLUN-001: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - Jun 24, 2024
P1, N=18, Recruiting, Sponsor: Shanghai Juncell Therapeutics
Not yet recruiting --> Recruiting
- | GC203 TIL / Gencells Therapeutics
Trial primary completion date, Metastases: Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov) - Jun 21, 2024
P1, N=50, Recruiting, Sponsor: Shanghai Juncell Therapeutics
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2024 --> Mar 2025
- || GC203 TIL / Gencells Therapeutics
New P1 trial, Metastases: KUNLUN-001: Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - Apr 19, 2024
P1, N=18, Not yet recruiting, Sponsor: Shanghai Juncell Therapeutics
- || GC203 TIL / Gencells Therapeutics
New P1 trial, Metastases: Study on TIL Engineered With Membrane-Binding Cytokine for the Treatment of Advanced Gynecologic Tumors (clinicaltrials.gov) - Jul 21, 2022
P1, N=50, Recruiting, Sponsor: Shanghai Juncell Therapeutics